Pharmacy Data Warehouse

This is an individual justification for a bridge action, resulting in an award of a Firm Fixed Price (FFP) modification to extend the period of performance for approximately16 months or July 24, 2024, for the General Dynamics Information Technology, Inc. (GDIT), Pharmacy Data Warehouse (PDW) task order for the management of TRICARE pharmacy transactionsdata repository. This bridge action will continue services supported under task order HHSN316201200013W / HT9402-14-F-0006.This bridge action is needed because the re-compete requirement was placed on hold due to lapse in funding and to allow for a GOGO version of the PDW to be built. The bridge action is needed to avoid a lapse in service . The current task order may not be extended after July 24, 2024 as the NIH contract does not allowperformance under task orders to exceed 10 years.Failure to extend the PDW task order will create a disruption in services and patient safety issues affecting all TRICARE beneficiaries using the DHA

Pharmacy Benefit by not being able to providecrucial commercial drug data to Government agencies in regard to a beneficiary's drug contradiction information, disproportionate drug use, and/or excessive prescriptions written by providers.Additionally, Military Health System (MHS) staff, the commercial pharmacy industry, DHA Program Integrity (PI), and Government agencies external to DHA will be negatively impacted becausethey rely on the data provided from the pharmacy data warehouse for analysis relating to Congressional reports involving pharmacoeconomics, utilization, trending, fraud waste and abuse, and,outcomes research.Failure to extend the task order will result in the following risks: Inability for DHA to continue the congressionally mandated Federal Pricing Refund Program ; Reduced ability for DHA to provide MHS Readiness tools and data used by the Military Treatment Facilities (MTFs) and deploying units; Reduced ability for DHA to provide analysis relating to DHA Program Integrity investigations and Congressional reports on pharmacoeconomics, utilization, trending, Opioid utilization, fraudwaste and abuse, as well as outcomes research; and Reduced ability for DHA to provide daily retail immunization, to include COVID 19 data for the DHA Director and the Secretary of Defense.